The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice
W Sun, L He, H Zhang, X Tian, Z Bai, L Sun… - Signal transduction and …, 2021 - nature.com
As COVID-19 continues to spread rapidly worldwide and variants continue to emerge, the
development and deployment of safe and effective vaccines are urgently needed. Here, we …
development and deployment of safe and effective vaccines are urgently needed. Here, we …
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B. 1.351 and B. 1.1. 7
RJ Fischer, N van Doremalen, DR Adney… - Nature …, 2021 - nature.com
Abstract We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-
CoV-2 variants of concern (VOCs) B. 1.1. 7 and B. 1.351 in Syrian hamsters. We previously …
CoV-2 variants of concern (VOCs) B. 1.1. 7 and B. 1.351 in Syrian hamsters. We previously …
SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern
DW Hawman, K Meade-White, J Archer, SS Leventhal… - Elife, 2022 - elifesciences.org
Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late 2021 with
resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants …
resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants …
The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2
W Alturaiki, A Mubarak, A Al Jurayyan… - Human Vaccines & …, 2021 - Taylor & Francis
ABSTRACT SARS-CoV2 infection induces various degrees of infections ranging from
asymptomatic to severe cases and death. Virus/host interplay contributes substantially to …
asymptomatic to severe cases and death. Virus/host interplay contributes substantially to …
Nonhuman primate models for evaluation of SARS-CoV-2 vaccines
JA Neil, M Griffith, DI Godfrey, DFJ Purcell… - Expert Review of …, 2022 - Taylor & Francis
Introduction Evaluation of immunogenicity and efficacy in animal models provide critical data
in vaccine development. Nonhuman primates (NHPs) have been used extensively in the …
in vaccine development. Nonhuman primates (NHPs) have been used extensively in the …
Design, immunogenicity and efficacy of a Pan-SARS-CoV-2 synthetic DNA vaccine
CC Reed, K Schultheis, VM Andrade, R Kalia, J Tur… - bioRxiv, 2021 - biorxiv.org
First generation COVID-19 vaccines matched to the original Wuhan-Hu-1 (WT) strain are
showing reduced efficacy against emerging SARS-CoV-2 variants of concern (VOC). In …
showing reduced efficacy against emerging SARS-CoV-2 variants of concern (VOC). In …
Ad26. COV2. S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques
M Aid, SJ Vidal, C Piedra-Mora, S Ducat… - PLoS …, 2022 - journals.plos.org
Syrian golden hamsters exhibit features of severe disease after SARS-CoV-2 WA1/2020
challenge and are therefore useful models of COVID-19 pathogenesis and prevention with …
challenge and are therefore useful models of COVID-19 pathogenesis and prevention with …
[HTML][HTML] SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous …
DW Hawman, K Meade-White, J Archer, S Leventhal… - BioRxiv, 2021 - ncbi.nlm.nih.gov
Despite mass public health efforts, the SARS-CoV2 pandemic continues as of late-2021 with
resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants …
resurgent case numbers in many parts of the world. The emergence of SARS-CoV2 variants …
Influenza virus and SARS-CoV-2 vaccines
AM Sandor, MS Sturdivant, JPY Ting - The Journal of Immunology, 2021 - journals.aai.org
Seasonal influenza and the current COVID-19 pandemic represent looming global health
challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both …
challenges. Efficacious and safe vaccines remain the frontline tools for mitigating both …
Ethical Issues Involving the Development of COVID-19 Vaccines: Role of Vaccine Development, Clinical Trials, and Speed of Peer Review in Dissuading Public …
LMA Martin, GW Buck - Ethics in Biology, Engineering and …, 2021 - dl.begellhouse.com
Over 60% of the population in the United States received the SARS-Co-V type 2 messenger
RNA (mRNA) vaccine, manufactured by Pfizer-BioNTech and by Moderna. The pace at …
RNA (mRNA) vaccine, manufactured by Pfizer-BioNTech and by Moderna. The pace at …